View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 17, 2020

Zydus Cadila looks to expedite Covid-19 vaccine development

India-based pharmaceutical firm Zydus Cadila has launched a fast-tracked research programme to develop a vaccine against the disease caused by the new coronavirus, Covid-19.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

India-based pharmaceutical firm Zydus Cadila has launched a fast-tracked research programme to develop a vaccine against the disease caused by the new coronavirus, Covid-19.

The company’s teams in India and Europe will leverage two different methods to develop the vaccine.

One approach involves the creation of a DNA vaccine against the viral membrane protein required for the virus’ entry into the cell.

In host cells, the delivered plasmid DNA would translate into the viral protein and trigger an immune response via the cellular and humoral arms of the immune system. These arms are known to help to protect from disease and viral clearance.

The second method will see the development of a live attenuated recombinant measles virus (rMV) vectored vaccine to fight the new coronavirus.

Codon-optimised proteins of the new coronavirus, expressed by rMV generated, will use reverse genetics to stimulate long-term neutralising antibodies that protect against the infection.

A team at the company’s Vaccine Technology Centre in India is working on the plasmid DNA vaccine, while its research unit at Etna Biotech in Europe is working on measles reverse genetics technology.

Zydus Group chairman Pankaj Patel said: “There is an urgent and pressing need to develop a safe and efficacious vaccine that can prevent the spread of this deadly virus. Our researchers are working to bring a speedy solution to this most devastating outbreak in recent times.”

The company’s manufacturing facilities for recombinant antigens and measles-containing vaccines will allow scale-up both vaccine candidates’ production.

Last week, biotechnology firm Codagenix partnered with vaccine manufacturer Serum Institute of India to co-develop a vaccine against Covid-19.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology